Skip to main content

Table 2 Expected lifetime Quality adjusted life-years (QALYs), Costs (US dollars 2017) and incremental cost-effectiveness ratios (ICERs) of Sofosbuvir-based regimens in Cameroon, Côte d’Ivoire and Senegal (each modeled cohort = 10,000 mono-infected patients)

From: Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa

  QALYs
(mean [95%CI]), per patient
Costs
(mean [95%CI]), per patient (2017 USD)
ICERs
(mean [95%CI]), per QALY
Probability of being CEa
Cam. Côte d’Iv. Sen. Cam. Côte d’Iv. Sen. Cam. Côte d’Iv. Sen. Cam. Côte d’Iv. Sen.
Scenario 1: originator DAA prices
 Status-quo 8.4 [8.1; 8.8] 7.9 [7.6; 8.3] 8.7 [8.3; 9.1] 274.8 [218.5; 336.8] 256.0 [202.6; 311.8] 387.1 [305.4; 473.3]
 SOF/ DCV 10.1 [9.9; 10.4] 9.4 [9.2; 9.7] 10.5 [10.2; 10.8] 1695.1 [1651.7; 1738.1] 1560.6 [1520.3; 1600.4] 1689.4 [1645.5; 1735.7] Dominated Dominated Dominated    
 SOF/ VEL 10.2 [9.9; 10.4] 9.5 [9.2; 9.7] 10.6 [10.3; 10.8] 1340.7 [1306.2; 1376.3] 1206.9 [1176.0; 1239.0] 1334.6 [1297.2; 1373.3] 621.0 [481.5; 819.2] 632.0 [483.1; 850.5] 525.6 [402.5; 704.9] 0.86 0.93 0.96
 SOF/ RBV 10.1 [9.8; 10.4] 9.4 [9.1; 9.6] 10.5 [10.1; 10.8] 1783.3 [1735.6; 1832.3] 1559.5 [1518.1; 1602.0] 1743.9 [1695.2; 1795.9] Dominated Dominated Dominated    
 SOF/ LDV 10.1 [9.8; 10.3] 9.4 [9.1; 9.6] 10.4 [10.2; 10.7] 1818.1 [1771.3; 1866.7] 1655.3 [1613.3; 1698.6] 1802.2 [1753.0; 1853.2] Dominated Dominated Dominated    
Scenario 2: generic DAA prices
 Status-quo 8.4 [8.1; 8.8] 7.9 [7.6; 8.3] 8.7 [8.3; 9.1] 274.8 [218.5; 336.8] 256.0 [202.6; 311.8] 387.1 [305.4; 473.3]
 SOF/ DCV 10.1 [9.9; 10.4] 9.4 [9.2; 9.7] 10.5 [10.2; 10.8] 639.0 [618.3; 661.2] 504.5 [487.2; 523.3] 633.5 [607.9; 661.8] 215.8 [157.2; 297.2] 168.3 [117.1; 237.5] 139.4 [85.9; 208.4] 1 1 1
 SOF/ VEL 10.2 [9.9; 10.4] 9.5 [9.2; 9.7] 10.6 [10.3; 10.8] 891.2 [866.5; 917.2] 757.0 [735.2; 779.6] 885.0 [856.6; 916.5] 2522 [2483; 5104] 2525 [2480; 6427] 2515 [2487-5073] 0 0 0
 SOF/ LDV 10.1 [9.8; 10.3] 9.4 [9.1; 9.6] 10.4 [10.2; 10.7] 1046.1 [1016.3; 1077.4] 882.9 [857.0; 909.6] 1029.7 [995.9; 1066.0] Dominated Dominated Dominated    
 SOF/ RBV 10.1 [9.8; 10.4] 9.4 [9.1; 9.6] 10.5 [10.2; 10.8] 1153.3 [1120.7; 1187.7] 928.8 [901.6; 958.8] 1113.4 [1076.5; 1154.4] Dominated Dominated Dominated    
  1. Abbreviations: Cam. Cameroon, CE Cost-effective, Côte d’Iv. Côte d’Ivoire, ICER Incremental cost-effectiveness ratio, QALYs quality adjusted life-years, Sen. Senegal, SOF/DCV Sofosbuvir+Daclatasvir, SOF/LDV Sofosbuvir+Ledipasvir, SOF/RBV Sofosbuvir + Ribavirin, SOF/VEL Sofosbuvir+Velpatasvir
  2. aAt a cost-effectiveness threshold of 0.5 times the country per-capita gross domestic product